{"name":"Ardea Biosciences, Inc.","slug":"ardea-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Febuxostat 40 mg","genericName":"Febuxostat 40 mg","slug":"febuxostat-40-mg","indication":"Other","status":"marketed"},{"name":"Zyloprim® 300 mg","genericName":"Zyloprim® 300 mg","slug":"zyloprim-300-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Febuxostat 40 mg","genericName":"Febuxostat 40 mg","slug":"febuxostat-40-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zyloprim® 300 mg","genericName":"Zyloprim® 300 mg","slug":"zyloprim-300-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOVDl5b0ZpOG91ZXMxeG5fREZOd1MwRkM3bTRsSVUyWnhtcFJ1MTdxNmpuZFZWYVlQWDljdE4yQ2JJaWxrQW9hOERXazJtVWJjOWZXTHB2S3BKSzRiX3VxbkVCUWdrdm96aVByZjUzcnZqRGVrMU5zODk5a25MLVF4SlZ2XzRKZGxOODdQZUZsWlc?oc=5","date":"2025-09-30","type":"pipeline","source":"BioPharma Dive","summary":"Crystalys debuts with $205M and plans for a better gout drug - BioPharma Dive","headline":"Crystalys debuts with $205M and plans for a better gout drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNeGF1UVdFOWVVLS1HMTB4d19QTmNnMnNIOFN3c0JpMTB1ME1Hdk5JRVVaX0xMUHQwWnNhempHSjZzMUpZeXU1WHNQakYxZHJLNzVKZVdQTEgxS0FNLUVZLVlaT1BOYmoyRmZ2NUlwMkR4Z3J1ZUNTWWplaU8xdkF1UlBiM1lIMm1kMF9N?oc=5","date":"2025-05-21","type":"pipeline","source":"citybiz","summary":"Q&A with Barry Quart, CEO at Connect Biopharma - citybiz","headline":"Q&A with Barry Quart, CEO at Connect Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQVWhWeWdSeXREb2Q2Z2otNXVDN3p1WWxOdm12bTBOZU9Wa1NYeC11a0pvUWhGek1BOTdBZmdzVEhfbTNtRjdOWF9USTh2YWY3RzY1bGFZNzZwLV9STnRGSm9uS1l3dWhSX1hzdGpIWWx1S29MbHNCcjFqVncxT1llVlU2U3Q5b1RPcHlUOFVzdkZBNW5wNVVDTVhFcTNBMjB6aWhkbWJEc0NUSk02cFBMaW9pcXFXUUtZcUpNRkRpVXNWaDBSbHRtajRaay1NTTBhM283dGVEWQ?oc=5","date":"2024-11-07","type":"trial","source":"BioSpace","summary":"Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - BioSpace","headline":"Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOVVdna0pZOW85Z2VsY0tURl9UNnRVNGNPdW1MdnktOV9zZElzYnhXdExCcmpQNTd5NEVmOFNWMUh1ZHoxWkh1TlFKU2lVU2pBU05VZEtmZWRJYUhlOTRzSEREQ1J6TnpXU2JFVmNXblBoRmhpb0lrU0JtNi1nM0cwYVo0b1U5dE1oTjRaaDItRHZ3UklUbVVj?oc=5","date":"2023-03-30","type":"pipeline","source":"citybiz","summary":"Zevra Therapeutics Appoints Wendy Dixon, Ph.D., To Board - citybiz","headline":"Zevra Therapeutics Appoints Wendy Dixon, Ph.D., To Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQMXdpVGplQ3ZEV3JoSTR3TGk2MlMzcUxZeU5GMDZEXzlLclFadzQ0ZktzRDhBVjRlNks0STZ1cGk4R2FLVmJZTW1odWxEV3FRVzRtS0ZhYzhrT0pndzBMbTFBaEZxclk2aWtqdWdjWXZmVVNBRVFyY3VFaFByZTE2NGZPeDVXWTBaMEhuQ0pFb2Vndm9taTBDZFZZYUVZSGZIWlh0Mm1uSjFPQTlr?oc=5","date":"2016-06-05","type":"pipeline","source":"Go Local Prov","summary":"FBI Raid East Side Home Early Friday Morning Tied to Insider Trading Says US Attorney in NY - Go Local Prov","headline":"FBI Raid East Side Home Early Friday Morning Tied to Insider Trading Says US Attorney in NY","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOQmxiRDBaMF9XXy1BSjRjUEY1WkFBUXdhT1JlOGMxdnV5UndSdHZZQWw3S3RKbC1xVGtSMms0U25JelIzMFlLV0VJVFR1d2tNM3NmNk9uOTVMTk1oLV9ZdEZFMWFMSzZYbGk5WGJ3TTJ1RFlreW0xY3VjM080RkxHcmszanphYmZONTRfSThocS1uYXV6U0d1cVJKSWVrQjYyYVhSenZfZngzWWZUbHlzQzFwc0dELU9zc01tcHIzYURaVW1RRjFLT1k5eklzTnhGWDFrdWxUTHR4OEZ5Q1BFdnNNS2ZlTER1UUozM0FscERCR2lTOXhKcQ?oc=5","date":"2016-04-26","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad - AstraZeneca","headline":"AstraZeneca enters into US licensing agreement with Ironwood Pharmaceuticals for lesinurad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQN1lzMnA1RmYwSGR3QTl4MktwU1Q5aVhKZXBZb3hhV3dIaDBpMFNfQTNwdHo5TXdiaDhEal9EM05peHluOGJnMF9nWWZiT2lDaUtTbVUtMmtyRjdxZnA0ZVZQTHZoRmNKRmdsY0duQ1lxOUJPUkpsUEJONkVRZlBDVGJKLVhENzVVWTV4LS1QNkxra0U?oc=5","date":"2013-05-03","type":"pipeline","source":"PMLiVE","summary":"AP Pharma overhauls senior management team - PMLiVE","headline":"AP Pharma overhauls senior management team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQejhZdmZieWFrQ2F3cXdOMUhnYzZTdEtwdzhrRmZjWGllUTlDQWJBRzVJWEtrcS1oakEybHZjTTNyUE90bzRCYmdHS3Y3bXRjNjdTM1FINDE0UUIxeU1aemJaX1ZtNlUtelJ6bHpXVmxtOE9mZmZ1LUxDSU9FNExqUW1FZDRjYlBKUUI5aXlwcjN2dGJzd3FiYkE0QzZNZVRQekhHMWROMUdaQ0JaVUw1eUdKTDF2R0g1N2tVM3FuWGZqSU9ZOEUxTg?oc=5","date":"2012-04-23","type":"trial","source":"AstraZeneca","summary":"AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase III development for gout - AstraZeneca","headline":"AstraZeneca to acquire Ardea Biosciences for $1 billion (net of existing cash) including lead product lesinurad in Phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNclJoME4yVjVkay0wN1lKVFhQdzg5VHdwUFU5NEVKTWN2aEU0ZHpuOVFPelN6bThSV0MzOVcxRXJNVWpvaWpYaVE2TzRsLWRLd2ZoOUR2X3pRcDhlM1poT0g2TVZTSFJOLXE2RFB5VEt1LWFWamM0eEk4Ri0zMjI3bHJhc2p3MHNMeDg4anVnWDVQLVg0VWNwcUpvMlhjaUJVZDdIV1RSVUZUMUF5NndfWVN4RQ?oc=5","date":"2011-05-26","type":"trial","source":"RTTNews","summary":"BioCryst Pharma Reveals Positive Data From Midstage Studies Of Gout Drug - RTTNews","headline":"BioCryst Pharma Reveals Positive Data From Midstage Studies Of Gout Drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFBweURhN1p0eUVSUF9iaGRUaTBGQ3duZmVnZXhocWpyVlBBLUNGc0k1MHFJZHJacmZwT3B6dGo0Yy1zMlJFd1FwdDhFcUU2X3EwSEZrMjJhbThicHFaV1lTYkNlUUJwMkhkampqdHpBRHJUQ1p4aXVkc3pxREM?oc=5","date":"2011-05-10","type":"pipeline","source":"WSJ","summary":"Best on the Street Stock Analysts: Pharmaceuticals - WSJ","headline":"Best on the Street Stock Analysts: Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPYkpsRzgwalNJNW40eW5IMkl0dVUxQWxoZS11M3RCcXhMRjNOUlhQc1dMaXNISk9xZXdYY29HYVp5YnMyZWVUSUFaQWVVWUpIR0VmVHJOc0E3cGVlWWtmTEhWZlhFS3JNQUotalNVWVozeUtfNnZ3M1hGWGxyTzdUZmVxMjEyVjhySzhNdDZHay0xeUJjRVV0Tzd4UXBCMHhHQUZTdHB5MFZnLUZmQnVXV1ExS0dqbnRUcjY5aUF3NVIzQ3dHd2dr?oc=5","date":"2010-01-07","type":"pipeline","source":"Fierce Biotech","summary":"Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or - Fierce Biotech","headline":"Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOSmo4TDJhcVN3b3BzMkFXQTJDS2dtX2pyMGNXUjRkN3VKT3ZNN1R2SVppTTdZUjUwOEtYNDE2N2x5N2tVYWFrMV9zaWIzUFV6blMyUVZPbWFzQkdRTTd0d2JmeUNfVzhmbk9RRjhPZ1NtTHZ2b1FqaHlmZHpvckplZFRrU2lvT1dGZjJodWZScE13WGMzb0lkN25hUjZ4X09Cdkpwd2tNdi16NnF3RzEzRHgteVlkMFZxbXUyV2N4NjBnYV8xM0RQcA?oc=5","date":"2009-04-28","type":"pipeline","source":"Fierce Biotech","summary":"Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer - Fierce Biotech","headline":"Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Can","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}